Naunyn-Schmiedeberg's Archives of Pharmacology, volume 393, issue 9, pages 1649-1658
Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats
Krasnova Marina
1
,
Kulikov Alexander
2
,
Okovityi Sergey
1
,
Ivkin Dmitry
1
,
Karpov Andrey
3
,
Kaschina Elena
4
,
Smirnov Alexey
2
Publication type: Journal Article
Publication date: 2020-05-06
Quartile SCImago
Q2
Quartile WOS
Q2
Impact factor: 3.6
ISSN: 00281298, 14321912
General Medicine
Pharmacology
Abstract
The study aimed to investigate the effects of the sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin on chronic heart failure (HF) in normoglycemic rats. The effects of empagliflozin were compared with the standard medications for HF, e.g., angiotensin-converting enzyme (ACE) inhibitor fosinopril, beta-blocker bisoprolol, and aldosterone antagonist spironolactone. Myocardial infarction (MI) was induced in male Wistar rats via permanent ligation of the left descending coronary artery. One-month post MI, 50 animals were randomized into 5 groups (n = 10): vehicle-treated, empagliflozin (1.0 mg/kg), fosinopril (10 mg/kg), bisoprolol (10 mg/kg), and spironolactone (20 mg/kg). All medications except empagliflozin were titrated within a month and administered per os daily for 3 months. Echocardiography, 24-hour urine volume test, and treadmill exercise tests were performed at the beginning and at the end of the study. Treatment with empagliflozin slowed the progression of left ventricular dysfunction: LV sizes and ejection fraction were not changed and the minute volume was significantly increased (from 52.0 ± 15.5 to 61.2 ± 21.2 ml/min) as compared with baseline. No deaths occurred in empagliflozin group. The 24-hour urine volume tends to be higher in empagliflozin and spironolactone groups than in vehicle and fosinopril group. Moreover, empagliflozin exhibited maximal physical exercise tolerance in comparison with all investigated groups (289 ± 27 s versus 183 ± 61 s in fosinopril group, 197 ± 95 s in bisoprolol group, and 47 ± 46 s in spironolactone group, p = 0.0035 for multiple comparisons). Sodium-glucose co-transporter 2 inhibitor empagliflozin reduced progression of left ventricular dysfunction and improved tolerance of physical exercise in normoglycemic rats with HF. Empagliflozin treatment was superior with respect to physical tolerance compared with fosinopril, bisoprolol, and spironolactone.
Citations by journals
|
1
2
3
|
|
|
International Journal of Molecular Sciences
|
International Journal of Molecular Sciences
3 publications, 42.86%
|
|
Viruses
|
Viruses
1 publication, 14.29%
|
|
Cardiovascular Diabetology
|
Cardiovascular Diabetology
1 publication, 14.29%
|
|
Naunyn-Schmiedeberg's Archives of Pharmacology
|
Naunyn-Schmiedeberg's Archives of Pharmacology
1 publication, 14.29%
|
|
Drug development & registration
|
Drug development & registration
1 publication, 14.29%
|
|
1
2
3
|
Citations by publishers
|
1
2
3
4
|
|
|
Multidisciplinary Digital Publishing Institute (MDPI)
|
Multidisciplinary Digital Publishing Institute (MDPI)
4 publications, 57.14%
|
|
Springer Nature
|
Springer Nature
2 publications, 28.57%
|
|
Center of Pharmaceutical Analytics Ltd
|
Center of Pharmaceutical Analytics Ltd
1 publication, 14.29%
|
|
1
2
3
4
|
- We do not take into account publications that without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.
{"yearsCitations":{"type":"bar","data":{"show":true,"labels":[2021,2022,2023],"ids":[0,0,0],"codes":[0,0,0],"imageUrls":["","",""],"datasets":[{"label":"Citations number","data":[2,4,1],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6"],"percentage":["28.57","57.14","14.29"],"barThickness":null}]},"options":{"indexAxis":"x","maintainAspectRatio":true,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":1,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Citations per year","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"journals":{"type":"bar","data":{"show":true,"labels":["International Journal of Molecular Sciences","Viruses","Cardiovascular Diabetology","Naunyn-Schmiedeberg's Archives of Pharmacology","Drug development & registration"],"ids":[14627,2455,36,5278,26766],"codes":[0,0,0,0,0],"imageUrls":["\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/ewwj5yBvA6wToa4jkXRrcDjN2omUCp6UYltwKhS8_medium.webp"],"datasets":[{"label":"","data":[3,1,1,1,1],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":[42.86,14.29,14.29,14.29,14.29],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Journals","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"publishers":{"type":"bar","data":{"show":true,"labels":["Multidisciplinary Digital Publishing Institute (MDPI)","Springer Nature","Center of Pharmaceutical Analytics Ltd"],"ids":[202,8,7156],"codes":[0,0,0],"imageUrls":["\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/ewwj5yBvA6wToa4jkXRrcDjN2omUCp6UYltwKhS8_medium.webp"],"datasets":[{"label":"","data":[4,2,1],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6"],"percentage":[57.14,28.57,14.29],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Publishers","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}}}
Metrics
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Krasnova M. et al. Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats // Naunyn-Schmiedeberg's Archives of Pharmacology. 2020. Vol. 393. No. 9. pp. 1649-1658.
GOST all authors (up to 50)
Copy
Krasnova M., Kulikov A., Okovityi S., Ivkin D., Karpov A., Kaschina E., Smirnov A. Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats // Naunyn-Schmiedeberg's Archives of Pharmacology. 2020. Vol. 393. No. 9. pp. 1649-1658.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1007/s00210-020-01873-7
UR - https://doi.org/10.1007%2Fs00210-020-01873-7
TI - Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats
T2 - Naunyn-Schmiedeberg's Archives of Pharmacology
AU - Krasnova, Marina
AU - Kulikov, Alexander
AU - Okovityi, Sergey
AU - Ivkin, Dmitry
AU - Karpov, Andrey
AU - Kaschina, Elena
AU - Smirnov, Alexey
PY - 2020
DA - 2020/05/06 00:00:00
PB - Springer Nature
SP - 1649-1658
IS - 9
VL - 393
SN - 0028-1298
SN - 1432-1912
ER -
Cite this
BibTex
Copy
@article{2020_Krasnova,
author = {Marina Krasnova and Alexander Kulikov and Sergey Okovityi and Dmitry Ivkin and Andrey Karpov and Elena Kaschina and Alexey Smirnov},
title = {Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2020},
volume = {393},
publisher = {Springer Nature},
month = {may},
url = {https://doi.org/10.1007%2Fs00210-020-01873-7},
number = {9},
pages = {1649--1658},
doi = {10.1007/s00210-020-01873-7}
}
Cite this
MLA
Copy
Krasnova, Marina, et al. “Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats.” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 393, no. 9, May. 2020, pp. 1649-1658. https://doi.org/10.1007%2Fs00210-020-01873-7.